ORIC Pharmaceuticals (ORIC) has already reported preliminary results for three programs in its pipeline, which are: ORIC-944, ORIC-114 and ORIC-533. With respect to ORIC-944 for the treatment of ...

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 19, 2020 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address ...

Anticipated registrational development plans for ORIC-944 and ORIC-114 prioritized to focus on indications with strongest clinical validation and highest unmet need ORIC-944 initiation of first Phase ...

ORIC Pharmaceuticals is walking away from the lead program used to underpin its 2020 IPO after the cancer med fell short in several early-stage trials. ORIC, which stands for overcoming resistance in ...

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 18, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address ...

Announced completion of dose exploration portion of ORIC-944 Phase 1b clinical trial and presented data that continues to demonstrate potential best-in-class efficacy and safety Bolstered leadership ...

ORIC-533 continues to demonstrate a best-in-class CD73 inhibitor profile in preclinical analyses. In autologous ex vivo assays using bone marrow aspirates from patients with relapsed refractory ...

Reported rinzimetostat (formerly ORIC-944) Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds and initiated dose optimization ...

ORIC announced that it's throwing in the towel on the development of experimental cancer drug ORIC-101. The company has three other programs in early-stage clinical studies. It's not unusual for a ...